Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk

Genitourinary Cancer

Select black men are potential candidates for prostate hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer-a multicenter SEARCH cohort study

Prostate Cancer Prostatic Dis

Deivasigamani S, Adams ES, Stock S, Kotamarti S, Séguier D, Taha T, Howard LE, Aminsharifi A, Jibara G, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Klaassen Z, Guerrios-Rivera L, Freedland SJ, Polascik TJ

doi: 10.1038/s41391-024-00880-6

Genitourinary Cancer

A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer

Eur Urol

Dai YH, Chen PH, Lee DJ, Andrade G, Vallis KA

doi: 10.1016/j.eururo.2024.09.020

Genitourinary Cancer

Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort

Cancer Epidemiol Biomarkers Prev

Liss MA, Zeltser N, Zheng Y, Lopez C, Liu M, Patel Y, Yamaguchi TN, Eng SE, Tian M, Semmes OJ, Lin DW, Brooks JD, Wei JT, Klein EA, Tewari AK, Mosquera JM, Khani F, Robinson BD, Asad M, Troyer DA, Kagan J, Sanda MG, Thompson IM, Boutros PC, Leach RJ

doi: 10.1158/1055-9965.EPI-24-0326

Genitourinary Cancer

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial

Eur Urol

Armstrong AJ, Sartor O, de Bono J, Chi K, Fizazi K, Krause BJ, Herrmann K, Rahbar K, Tagawa ST, Saad F, Beer TM, Wu J, Mirante O, Morris MJ

doi: 10.1016/j.eururo.2024.08.021

Genitourinary Cancer

Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment

Prostate Cancer Prostatic Dis

Freedland SJ, Gao W, Lax A, Yang H, Ramaswamy K, Russell D, Hong A, Ivanova JI

doi: 10.1038/s41391-024-00894-0

Genitourinary Cancer

Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate Cancer

Eur Urol

Fendler WP, Grünwald V, Herrmann K, Hadaschik BA

doi: 10.1016/j.eururo.2024.10.007

Genitourinary Cancer

A Polygenic Risk Score for Late Bladder Toxicity Following Radiotherapy for Non-Metastatic Prostate Cancer

Cancer Epidemiol Biomarkers Prev

Farazi M, Yang X, Gehl CJ, Barnett GC, Burnet NG, Chang-Claude J, Parker CC, Dunning AM, Azria D, Choudhury A, Rancati T, De Ruysscher D, Seibold P, Sperk E, Talbot CJ, Veldeman L, Webb AJ, Elliott R, Aguado-Barrera ME, Carballo AM, Fuentes-Ríos O, Gómez-Caamaño A, Peleteiro P, Vega A, Ostrer H, Rosenstein BS, Saito S, Parliament M, Usmani N, Marples B, Chen Y, Morrow G, Messing E, Janelsins MC, Hall W, West CML, Auer PL, Kerns S

doi: 10.1158/1055-9965.EPI-24-1228

Genitourinary Cancer

Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer

Prostate Cancer Prostatic Dis

Incesu RB, Preisser F, Nohe F, Maurer T, Graefen M, Tilki D

doi: 10.1038/s41391-024-00930-z

Genitourinary Cancer

Does a Negative Prostate Biopsy Reduce the Risk of Prostate Cancer Reclassification in an Active Surveillance Protocol? An Updated Systematic Review and Meta-Analysis

Prostate

Bahri RA, Mohammadi A, Yar EZ, Rezayat M, Heshmat R, Aghamir SMK

doi: 10.1002/pros.24851

Related content

Select black men are potential candidates for prostate hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer-a multicenter SEARCH cohort study

A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer

Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial

Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment

Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate Cancer

A Polygenic Risk Score for Late Bladder Toxicity Following Radiotherapy for Non-Metastatic Prostate Cancer

Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer

Does a Negative Prostate Biopsy Reduce the Risk of Prostate Cancer Reclassification in an Active Surveillance Protocol? An Updated Systematic Review and Meta-Analysis